Browse studies, page 1091
Page 1091 of 1,203, newest first. Search them all at once, ranked by relevance, in Evidence Hub.
- Cardio/Kidney Composite End Points: A Post Hoc Analysis of the EMPA-REG OUTCOME Trial Journal of the American Heart Association, 2021
- Sodium-glucose cotransporter 2 inhibitors: renal outcomes according to baseline albuminuria Clinical kidney journal, 2021
- Initiation of New Glucose-Lowering Therapies May Act to Reduce Physical Activity Levels: Pooled Analysis From Three Randomized Trials Diabetes care, 2022
- Comparative effectiveness of Empagliflozin in reducing the burden of recurrent cardiovascular hospitalizations among older adults with diabetes in routine clinical care American heart journal, 2022
- Efficacy and Safety of Empagliflozin According to Background Diuretic Use in HFrEF: Post-Hoc Analysis of EMPEROR-Reduced JACC. Heart failure, 2024
- Empagliflozin improves high-sensitive cardiac troponin-I and high-density lipoprotein cholesterol in patients with type 2 diabetes mellitus and coronary artery disease: a post-hoc analysis of EMPA-CARD Trial Journal of diabetes and metabolic disorders, 2023
- Effect of Empagliflozin with or without the Addition of Evolocumab on HDL Subspecies in Individuals with Type 2 Diabetes Mellitus: A Post Hoc Analysis of the EXCEED-BHS3 Trial International journal of molecular sciences, 2024
- Ketone body levels and its associations with cardiac markers following an acute myocardial infarction: a post hoc analysis of the EMMY trial Cardiovascular diabetology, 2024
- Apelin and Copeptin Levels in Patients With Chronic SIAD Treated With Empagliflozin Journal of the Endocrine Society, 2024
- Impact of Empagliflozin on Glomerular Hyperfiltration and Albuminuria in Youth with Type 2 Diabetes: Post Hoc Analysis of DINAMO. Clinical journal of the American Society of Nephrology : CJASN, 2026
- Effect of Semaglutide on Measured vs Estimated Glomerular Filtration Rate Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2026
- All-Cause Mortality in Patients With Diabetes Under Treatment With Dapagliflozin: A Population-Based, Open-Cohort Study in The Health Improvement Network Database The Journal of clinical endocrinology and metabolism, 2017
- Urinary adenosine excretion in type 1 diabetes American journal of physiology. Renal physiology, 2017
- Characterization and implications of the initial estimated glomerular filtration rate 'dip' upon sodium-glucose co-transporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOME trial Kidney international, 2021
- Design of a prospective patient-level pooled analysis of two parallel trials of empagliflozin in patients with established heart failure European journal of heart failure, 2020
- Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial The lancet. Diabetes & endocrinology, 2022
- Twenty-Four Hour Blood Pressure Response to Empagliflozin and Its Determinants in Normotensive Non-diabetic Subjects Frontiers in cardiovascular medicine, 2022
- Effects of empagliflozin on cardiovascular and renal outcomes in heart failure with reduced ejection fraction according to age: a secondary analysis of EMPEROR-Reduced European journal of heart failure, 2022
- Influence of angiotensin receptor-neprilysin inhibition on the efficacy of Empagliflozin on cardiac structure and function in patients with chronic heart failure and a reduced ejection fraction: The Empire HF trial American heart journal plus : cardiology research and practice, 2023
- Greater Combined Reductions of HbA1c ≥ 1.0% and Body Weight Loss ≥ 5.0% or ≥ 10.0% with Orally Administered Semaglutide Versus Comparators Diabetes therapy : research, treatment and education of diabetes and related disorders, 2023
- Baseline Cardiovascular Risk Factor Control in Patients With Type 2 Diabetes and Coronary Disease Versus Stroke: Secondary Analysis of Cardiovascular Outcome Trials Stroke, 2023
- Ketone production and excretion even during mild hyperglycemia and the impact of sodium-glucose co-transporter inhibition in type 1 diabetes Diabetes research and clinical practice, 2024
- Empagliflozin and Risk of Incident Gout: Analysis from the EMPagliflozin Comparative Effectiveness and SafEty (EMPRISE) Cohort Study Journal of general internal medicine, 2024
- Comparative Cardiovascular Effectiveness of Empagliflozin Versus Dapagliflozin in Adults With Treated Type 2 Diabetes: A Target Trial Emulation Circulation, 2024
- A Systematic Review and Meta-Analysis of the Efficacy and Safety of Sodium-Glucose Cotransporter-2 Inhibitor in Patients Using Left Ventricular Assist Devices Journal of clinical medicine, 2024
- Empagliflozin in Heart Failure and Previous Coronary Revascularization: Insights From EMPEROR-Pooled JACC. Advances, 2026
- Empagliflozin reduces cardiovascular events, mortality and renal events in participants with type 2 diabetes after coronary artery bypass graft surgery: subanalysis of the EMPA-REG OUTCOME® randomised trial Diabetologia, 2018
- Effect of Dapagliflozin Versus Empagliflozin on Cardiovascular Death in Patients with Heart Failure Across the Spectrum of Ejection Fraction: Cost per Outcome Analysis American journal of cardiovascular drugs : drugs, devices, and other interventions, 2023
- Efficacy of Empagliflozin in Patients With Heart Failure Across Kidney Risk Categories Journal of the American College of Cardiology, 2023
- Angiotensin pathways under therapy with empagliflozin in patients with chronic heart failure ESC heart failure, 2023
- Secondary analyses to assess the profound effects of empagliflozin on endothelial function in patients with type 2 diabetes and established cardiovascular diseases: The placebo-controlled double-blind randomized effect of empagliflozin on endothelial function in cardiovascular high risk diabetes mellitus: Multi-center placebo-controlled double-blind randomized trial Journal of diabetes investigation, 2020
- Empagliflozin and uric acid metabolism in diabetes: A post hoc analysis of the EMPA-REG OUTCOME trial Diabetes, obesity & metabolism, 2022
- Empagliflozin reduces the risk of mortality and hospitalization for heart failure across Thrombolysis In Myocardial Infarction Risk Score for Heart Failure in Diabetes categories: Post hoc analysis of the EMPA-REG OUTCOME trial Diabetes, obesity & metabolism, 2020
- Empagliflozin in women with type 2 diabetes and cardiovascular disease - an analysis of EMPA-REG OUTCOME®. Diabetologia, 2018
- SGLT2 inhibitors and renal outcomes in type 2 diabetes with or without renal impairment: A systematic review and meta-analysis Primary care diabetes, 2018
- Reduction of Cardiovascular Risk and Improved Estimated Glomerular Filtration Rate by SGLT2 Inhibitors, Including Dapagliflozin, Is Consistent Across the Class: An Analysis of the Placebo Arm of EXSCEL. Diabetes care, 2019
- Effects of empagliflozin on reproductive system in men without diabetes Scientific reports, 2024
- Safety and efficacy of empagliflozin in elderly Japanese patients with type 2 diabetes mellitus: A post hoc analysis of data from the SACRA study Journal of clinical hypertension (Greenwich, Conn.), 2021
- Cardiovascular Benefit of Empagliflozin Across the Spectrum of Cardiovascular Risk Factor Control in the EMPA-REG OUTCOME Trial The Journal of clinical endocrinology and metabolism, 2020
- Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial European Heart Journal, 2021
- Renal effects of empagliflozin in patients hospitalized for acute heart failure: from the EMPULSE trial European Journal of Heart Failure, 2022
- Empagliflozin improves quality of life in nondiabetic HFrEF patients. Sub-analysis of the EMPATROPISM trial Diabetes & metabolic syndrome, 2022
- Effects of Empagliflozin on Symptoms, Physical Limitations, and Quality of Life in Patients Hospitalized for Acute Heart Failure: Results From the EMPULSE Trial Circulation, 2022
- IGFBP7 and left ventricular mass regression: a sub-analysis of the EMPA-HEART CardioLink-6 randomized clinical trial ESC Heart Failure, 2023
- Cost-effectiveness analysis of Empagliflozin in patients with heart failure with reduced ejection fraction in Japan based on the EMPEROR-reduced trial Journal of Cardiology, 2023
- Alterations in trimethylamine-N-oxide in response to Empagliflozin therapy: a secondary analysis of the EMMY trial Cardiovascular Diabetology, 2023
- Mineralocorticoid receptor antagonist use and the effects of empagliflozin on clinical outcomes in patients admitted for acute heart failure: Findings from EMPULSE European Journal of Heart Failure, 2023
- Clinical trial designs to assess treatment effects on glomerular filtration rate decline Kidney International, 2024
- Concentration‐dependent clinical and prognostic importance of high‐sensitivity cardiac troponin T in heart failure and a reduced ejection fraction and the influence of empagliflozin: the EMPEROR‐Reduced trial European Journal of Heart Failure, 2021
- Effects of empagliflozin on first and recurrent clinical events in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a secondary analysis of the EMPA-REG OUTCOME trial The Lancet Diabetes and Endocrinology, 2020
- The effect of empagliflozin on renal outcomes compared to sitagliptin with type 2 diabetes: target trial emulation using electronic medical records International Journal of Clinical Pharmacy, 2025
- Letter by Tsuda Regarding Article, "Effect of Empagliflozin on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The EMPA-HEART CardioLink-6 Randomized Clinical Trial". Circulation, 2020
- Effect of empagliflozin on reducing the no-reflow phenomenon in patients with ST-elevation myocardial infarction: rationale and design of the EMPA-PCI trial European Heart Journal Open, 2025
- Effects of empagliflozin treatment on glycerol-derived hepatic gluconeogenesis in obese adults: a randomized clinical trial Obesity, 2020
- Empagliflozin Leads to Faster Improvement in Arterial Stiffness Compared to Dapagliflozin: A Double-Blind Clinical Life, 2025
- Comparison of Semaglutide or Dulaglutide Versus Empagliflozin for Risk for Death and Cardiovascular Outcomes Among Patients With Type 2 Diabetes : Two Target Trial Emulation Studies Annals of Internal Medicine, 2025
- Oral Semaglutide Versus Empagliflozin, Sitagliptin and Liraglutide in the UK: Long-Term Cost-Effectiveness Analyses Based on the PIONEER Clinical Trial Programme Diabetes Therapy, 2019
- Differences Between Randomized Clinical Trial Participants and Real-World Empagliflozin Users and the Changes in Their Glycated Hemoglobin Levels JAMA Network Open, 2020
- Empagliflozin in heart failure patients with reduced ejection fraction: a randomized clinical trial (Empire HF) Trials, 2019
- A randomized clinical trial evaluating the effect of empagliflozin on triglycerides in obese adults: Role of visceral fat Metabolism Open, 2021
- Effect of Empagliflozin on Blood Volume Redistribution in Patients With Chronic Heart Failure and Reduced Ejection Fraction: An Analysis From the Empire HF Randomized Clinical Trial Circulation: Heart Failure, 2021
- Reduction of cardiac adipose tissue volume with short‐term empagliflozin treatment in patients with type 2 diabetes: A substudy from the SIMPLE randomized clinical trial Diabetes, obesity and metabolism, 2022
- Comparison of effects of Empagliflozin and Linagliptin on renal function and glycaemic control: a double-blind, randomized clinical trial Clinical Diabetes and Endocrinology, 2022
- Empagliflozin and Left Ventricular Remodeling in People Without Diabetes: Primary Results of the EMPA-HEART 2 CardioLink-7 Randomized Clinical Trial Circulation, 2022
- Randomized Clinical Trial on Efficacy of Empagliflozin Versus Sitagliptin, In Addition to Metformin in Type 2 Diabetic Patients Cureus, 2022
- Safety and efficacy of Empagliflozin in Pakistani Muslim patients with type 2 diabetes (SAFE-PAK); a randomized clinical trial BMC Endocrine Disorders, 2022
- Rationale and design of the EMPA-ELDERLY trial: a randomised, double-blind, placebo-controlled, 52-week clinical trial of the efficacy and safety of the sodium–glucose cotransporter-2 inhibitor empagliflozin in elderly Japanese patients with type 2 diabetes BMJ Open, 2021
- Using real-world data for supporting regulatory decision making: Comparison of cardiovascular and safety outcomes of an empagliflozin randomized clinical trial versus real-world data Frontiers in Pharmacology, 2022
- Public Health Impact and Cost-Effectiveness of Empagliflozin (JARDIANCE®) in the Treatment of Patients with Heart Failure with Preserved Ejection Fraction in France, Based on the EMPEROR-Preserved Clinical Trial PharmacoEconomics - Open, 2023
- Pharmacometrics enhanced Bayesian borrowing approach to improve clinical trial efficiency: Case of empagliflozin in type 2 diabetes CPT: Pharmacometrics & Systems Pharmacology, 2023
- Effects of semaglutide and empagliflozin on oxygenation, vascular autoregulation, and central thickness of the retina in people with type 2 diabetes: A prespecified secondary analysis of a randomised clinical trial Journal of diabetes and its complications, 2023
- Evaluation of urate-lowering efficacy of isolated and combined use of febuxostat and empagliflozin in patients with gout and type 2 diabetes mellitus (OPORA Clinical Trial) Meditsinskiy sovet = Medical Council, 2024
- Empagliflozin and left atrial function in patients with type 2 diabetes mellitus and coronary artery disease: insight from the EMPA-HEART CardioLink‐6 randomized clinical trial Cardiovascular Diabetology, 2024
- Empagliflozin add‐on therapy is superior to metformin monotherapy in diabetic patients with NAFLD: An open‐label, single‐center, pilot clinical trial Journal of general and family medicine, 2024
- Cost-Effectiveness of Empagliflozin (JARDIANCE®) in the Treatment of Patients with Chronic Kidney Disease in France, Based on the EMPA-KIDNEY Clinical Trial Clinical drug investigation, 2024
- Empagliflozin and Dapagliflozin Improve Endothelial Function in Mexican Patients with Type 2 Diabetes Mellitus: A Double-Blind Clinical Trial Journal of Cardiovascular Development and Disease, 2024
- Empagliflozin in children with glycogen storage disease-associated inflammatory bowel disease: a prospective, single-arm, open-label clinical trial Scientific Reports, 2024
- Empagliflozin Repurposing for Lafora Disease: A Pilot Clinical Trial and Preclinical Investigation of Novel Therapeutic Targets Methods and Protocols, 2025
- The Spironolactone Initiation Registry Randomized Interventional Trial in Heart Failure with Preserved Ejection Fraction (SPIRRIT-HFpEF): Rationale and design European journal of heart failure, 2024
- Sodium glucose co-transporter 2 inhibition with empagliflozin on metabolic, cardiac and renal outcomes in recent cardiac transplant recipients (EMPA-HTx): protocol for a randomised controlled trial BMJ open, 2023
- Empagliflozin, irrespective of blood pressure, improves outcomes in heart failure with preserved ejection fraction: the EMPEROR-Preserved trial European heart journal, 2023
- The win ratio method in heart failure trials: lessons learnt from EMPULSE European journal of heart failure, 2023
- Methods Article for a Study Protocol: Study Design and Baseline Characteristics for Aldosterone Synthase Inhibition in Chronic Kidney Disease American journal of nephrology, 2024
- Efficacy and safety of empagliflozin in combination with insulin in Chinese patients with type 2 diabetes and insufficient glycaemic control: A phase III, randomized, double-blind, placebo-controlled, parallel study Diabetes, obesity & metabolism, 2023
- Safety, Growth, and Development After Dapagliflozin or Saxagliptin in Children With Type 2 Diabetes (T2NOW Follow-Up) The Journal of clinical endocrinology and metabolism, 2025
- Recency of Heart Failure Hospitalization, Outcomes, and the Effect of Empagliflozin: An EMPEROR-Pooled Analysis JACC. Heart failure, 2023
- IMPROVE-DiCE, a 2-Part, Open-Label, Phase 2a Trial Evaluating the Safety and Effectiveness of Ninerafaxstat in Patients With Cardiometabolic Syndromes Circulation, 2026
- Outcomes With Finerenone by Baseline Treatment Goals in Type 2 Diabetes and Chronic Kidney Disease: A FIDELITY Analysis Diabetes, obesity & metabolism, 2026
- Effect of sodium-glucose co-transporter-2 inhibitors on survival free of organ support in patients hospitalised for COVID-19 (ACTIV-4a): a pragmatic, multicentre, open-label, randomised, controlled, platform trial The lancet. Diabetes & endocrinology, 2024
- Effects of dapagliflozin on blood volume status and vascular outcomes in clinically stabilized heart failure patients after an acute decompensated heart failure event (DAPA-VOLVO study): Protocol of a double-blind randomized controlled clinical trial PloS one, 2025
- Rationale and design of Dapagliflozin vErsus SacubiTrIl-valsartaN therapY in Heart Failure with reduced ejection fraction (DESTINY-HF): a pragmatic randomised controlled trial protocol BMJ open, 2024
- Randomized controlled clinical trial of Shenzhuo Formula in the treatment of macroalbuminuria in diabetic kidney disease and its inflammation-modulating mechanisms Precision clinical medicine, 2025
- Effects of empagliflozin on cardiac structure, function and biomarkers in patients with heart failure with preserved ejection fraction: study protocol for a randomised, placebo-controlled prospective trial BMJ open, 2023
- Effects of SGLT2 inhibitors on cardiac autonomic activity and ventricular remodeling in patients with acute myocardial infarction: study protocol for a clinical trial Trials, 2025
- Changes in β-Cell Function and Insulin Sensitivity During Treatment With Dapagliflozin Alone or in Combination With Exenatide in Type 2 Diabetes Diabetes care, 2025
- Effect of administration and withdrawal of the sodium-glucose cotransporter 2 inhibitor, tofogliflozin, on renal protection in individuals with type 2 diabetes mellitus and diabetic nephropathy: A multicenter, single-arm study (RESTORE-nephropathy study) Journal of diabetes investigation, 2025
- EVOLUTION-HF DEallEF: A non-interventional study of patients with heart failure initiated on dapagliflozin: study design ESC heart failure, 2025
- Targeting epicardial adipose tissue in heart failure with preserved ejection fraction: exploring the dapagliflozin connection BMC cardiovascular disorders, 2026
- Effects of Empagliflozin in Type 2 Diabetes With and Without Chronic Kidney Disease and Nondiabetic Chronic Kidney Disease: Protocol for 3 Crossover Randomized Controlled Trials (SiRENA Project) JMIR research protocols, 2024
- SGLT2 inhibitor with and without ALDosterone AntagonIst for heart failure with preserved ejection fraction: Design paper ESC heart failure, 2025
